GlassScriptPhysician profile
Omar Khan
NPI 1285196030
$2,048.00
in general payments reported to CMS, 2019-2025
14 companies · $440 in 2025
The $440 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $198 · 2023: $423 · 2024: $988 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.96 | 2022-2025 | |
| Fujifilm Healthcare Americas Corporation | $250.00 | 2024 | Utaswako Afp-L3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.38 | 2023-2025 | Xifaxan |
| Boston Scientific Corporation | $178.29 | 2023-2025 | Resolution 360 Clip, Exalt Model D, Spyglass |
| Janssen Biotech, INC. | $151.92 | 2024-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $138.95 | 2022-2024 | Entyvio |
| Daiichi Sankyo INC. | $90.83 | 2022-2023 | Injectafer |
| Madrigal Pharmaceuticals | $83.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $82.30 | 2024 | Stelara |
| Genzyme Corporation | $74.69 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $21.16 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.52 | 2024 | Terlivaz |
| Gilead Sciences, INC. | $15.89 | 2023 | Epclusa |
| Celgene Corporation | $14.69 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.